NCT00511082
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma No drug interventions treatment 1 unknown_status NCT00923910
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood treatment 1 / 2 completed NCT00129090
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma treatment 3 completed NCT00089284
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL treatment 1 / 2 terminated NCT01087333
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment No drug interventions Not Available Not Available recruiting NCT03198234
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders No drug interventions treatment 1 terminated NCT05144347
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT04696705
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients No drug interventions treatment 0 recruiting NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs treatment 2 terminated NCT02071888
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors treatment 1 completed NCT01983761
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation treatment 1 / 2 unknown_status NCT01527838
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit No drug interventions treatment 1 completed NCT01479387
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan Not Available Not Available completed NCT01448928
Zevalin Post-marketing Surveillance in Japan Not Available Not Available completed NCT01108341
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT00889798
Tumor Registry of Lymphatic Neoplasia No drug interventions Not Available Not Available completed NCT00614042
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma treatment 1 completed NCT00185679
Haploid Allogeneic Transplant Using the CliniMACS System No drug interventions treatment 2 terminated NCT00796731
SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma treatment 1 completed NCT06137144
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. No drug interventions treatment 1 / 2 recruiting NCT02559583
Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America No drug interventions Not Available Not Available completed NCT02186574
Tenofovir to Prevent HBV Reactivation treatment 3 unknown_status NCT01561911
A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment No drug interventions Not Available 1 completed NCT00587054
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders No drug interventions treatment 2 completed NCT00549185
Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma treatment 1 completed NCT02110563
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma No drug interventions treatment 1 terminated NCT06385522
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System No drug interventions treatment 1 not_yet_recruiting NCT03463057
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL treatment 2 active_not_recruiting NCT00185692
Allogeneic Transplantation From Related Haploidentical Donors treatment 2 completed NCT00891592
Umbilical Cord Blood Transplant for Hematological Malignancies No drug interventions treatment 1 completed NCT05879744
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) No drug interventions treatment 1 active_not_recruiting NCT03789240
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma treatment 2 active_not_recruiting NCT00333190
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation No drug interventions prevention Not Available completed NCT03739502
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant No drug interventions treatment 2 recruiting NCT04840784
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML No drug interventions treatment 1 terminated NCT04002947
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT06119685
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers treatment 1 / 2 recruiting NCT02315612
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies No drug interventions treatment 1 active_not_recruiting NCT05371054
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies treatment 1 / 2 recruiting NCT06486337
CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT05665062
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies treatment 1 recruiting NCT04139252
A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients No drug interventions Not Available Not Available active_not_recruiting NCT03465540
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies treatment 1 terminated NCT05365100
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL No drug interventions treatment 1 / 2 withdrawn NCT04555811
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL treatment 1 active_not_recruiting NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT02702492
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) treatment 1 terminated NCT05641428
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL No drug interventions treatment 2 recruiting NCT04639739
Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. treatment 0 not_yet_recruiting NCT04440436
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients treatment 1 / 2 recruiting NCT03535753
Safety and Efficacy Evaluation of Decitabine With R-GDP treatment 1 unknown_status NCT03527147
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) treatment 1 completed NCT02847949
A Study of IGN002 for Refractory NHL No drug interventions treatment 1 withdrawn NCT01101581
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL treatment 1 / 2 withdrawn NCT00814983
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft No drug interventions treatment 1 / 2 terminated NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL treatment 1 / 2 completed NCT00515892
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease treatment 1 unknown_status NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT00471367
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 No drug interventions treatment 1 terminated NCT00421395
Safety Study of NHL With 90Y-hLL2 IgG treatment 1 / 2 completed NCT00342121
Influence of Corn Farming on the Immune System No drug interventions Not Available Not Available completed NCT00985140
Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides No drug interventions Not Available Not Available terminated NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment Not Available Not Available completed NCT00880581
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas treatment 2 completed NCT00186290
Allo BMT in Advanced Leukemia or High Grade Lymphoma No drug interventions treatment Not Available completed NCT00991211
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab treatment 3 completed NCT01085058
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy diagnostic 2 / 3 completed NCT01078922
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas treatment 2 terminated NCT00186394
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT02846935
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies treatment 0 completed NCT01870479
Music & Cancer - Live Music During Chemotherapy No drug interventions supportive_care Not Available completed NCT01567475
The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas treatment 1 completed NCT00086034
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma treatment 2 completed NCT01452334
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy No drug interventions treatment 1 withdrawn NCT05096234
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma No drug interventions diagnostic 2 recruiting NCT01392716
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT03075696
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma treatment 1 / 2 recruiting NCT01598558
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT diagnostic Not Available withdrawn NCT01200758
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma treatment 3 completed NCT00622258
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 1 completed NCT01350258
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps treatment 1 / 2 terminated NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives treatment 2 terminated NCT01073163
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) treatment 3 completed NCT06520163
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma treatment 3 recruiting NCT01549886
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma treatment 2 terminated NCT00499239
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) treatment 1 / 2 terminated NCT01655225
A Study of LY3023414 in Participants With Advanced Cancer treatment 1 completed NCT01910025
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy treatment 2 completed NCT00051025
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT02003625
Meloxicam vs Placebo for Mobilization treatment 2 completed NCT05191225
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study treatment 4 unknown_status NCT00785330
Allo-hNHL (FluBuCy) treatment 2 completed NCT01059630
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) treatment 3 completed NCT04152148
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients No drug interventions treatment 1 completed NCT02087657
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation No drug interventions treatment Not Available unknown_status NCT03198026
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas treatment 2 recruiting NCT00652626
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function other 1 completed NCT01840566
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT00582166
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance treatment 2 terminated NCT00042666
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. treatment 2 completed NCT01203020
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation treatment 2 completed NCT00712582
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma treatment 2 completed NCT01090973
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) treatment 2 terminated NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT00558727
Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT01087294
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 completed NCT01119794
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab treatment 2 terminated NCT00251394
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma treatment 2 completed NCT00256191
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies treatment 1 completed NCT00969462
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma treatment 4 completed NCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies treatment 1 completed NCT01930162
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant basic_science 2 completed NCT00184080
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT03123029
Expanded Access to Venetoclax Not Available Not Available available NCT01594229
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 1 completed NCT00434629
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant treatment 1 completed NCT04226989
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy No drug interventions treatment 0 unknown_status NCT00066092
Pegfilgrastim PBPC Mobilization Study treatment 2 completed NCT00710892
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene No drug interventions treatment 1 active_not_recruiting NCT01854567
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT01068301
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation treatment 1 completed NCT04028804
FLT PET: A Pilot Study in Lymphoma Patients No drug interventions Not Available Not Available completed NCT03226704
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing No drug interventions Not Available Not Available enrolling_by_invitation NCT00596804
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT00504972
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies No drug interventions treatment 1 completed NCT01988272
Imaging Based Dosimetry for Individualized Internal Emitter Therapy No drug interventions Not Available Not Available completed NCT01332968
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) treatment 3 completed NCT01149668
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer treatment 1 completed NCT04666168
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma treatment Not Available recruiting NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia treatment 2 completed NCT01969669
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 basic_science 1 completed NCT00201669
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma treatment 2 completed NCT01321346
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies treatment 1 completed NCT01336712
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases No drug interventions treatment 2 completed NCT00587912
AIDS and Cancer Specimen Bank (ACSB) No drug interventions Not Available Not Available completed NCT00797810
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults treatment 4 unknown_status NCT00691210
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies treatment 1 completed NCT00438581
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma treatment 2 unknown_status NCT02683395
A Study of PLX51107 in Advanced Malignancies treatment 1 terminated NCT00777114
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy treatment 1 completed NCT01767714
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation treatment 3 completed NCT01659255
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL treatment 1 completed NCT00162955
Prevention of CHOP-induced Chronic Cardiotoxicity prevention 4 completed NCT00048555
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT00117455
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma treatment 2 completed NCT01296555
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer treatment 1 terminated NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders treatment 2 completed NCT00387023
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma treatment Not Available completed NCT00090038
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma treatment 4 completed NCT01768338
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma treatment 1 completed NCT00336843
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma treatment 2 completed NCT00720603
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. Not Available Not Available no_longer_available NCT01643603
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies treatment 1 terminated NCT04532203
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies No drug interventions treatment 0 recruiting NCT00352703
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation prevention 4 completed NCT01205503
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release treatment 2 completed NCT06066203
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies No drug interventions treatment 1 / 2 recruiting NCT01192464
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma No drug interventions treatment 1 active_not_recruiting NCT00192764
High Dose CHOP in Lymphoma treatment 2 completed NCT00400764
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas treatment 1 / 2 terminated NCT00361621
Ph II CHOP+Velcade in Mediastinal LBCL treatment 2 terminated NCT02078102
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma treatment 2 completed NCT06206902
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma No drug interventions treatment 1 recruiting NCT01060384
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT03027284
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer treatment 1 completed NCT03893682
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas treatment 1 active_not_recruiting NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) treatment 2 recruiting NCT00131014
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies No drug interventions Not Available Not Available recruiting NCT01592370
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma treatment 1 / 2 completed NCT02356159
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation treatment 1 / 2 active_not_recruiting NCT00923442
Biology Studies of Hematologic Cancers No drug interventions Not Available Not Available enrolling_by_invitation NCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL treatment 2 recruiting NCT00877214
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas treatment 3 active_not_recruiting NCT01456351
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab treatment 3 completed NCT05618028
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets No drug interventions treatment 1 recruiting NCT03533283
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma treatment 1 / 2 active_not_recruiting NCT04188678
Resiliency in Older Adults Undergoing Bone Marrow Transplant No drug interventions other Not Available active_not_recruiting NCT00848601
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma other 1 terminated NCT02328014
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies treatment 1 / 2 active_not_recruiting NCT02507336
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 supportive_care 2 completed NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 recruiting NCT01555892
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE No drug interventions treatment 1 recruiting NCT05623982
Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma No drug interventions treatment 1 / 2 recruiting NCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial treatment 3 active_not_recruiting NCT04661007
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) treatment 1 / 2 recruiting NCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers treatment 1 active_not_recruiting NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No drug interventions Not Available Not Available recruiting NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT03955783
Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies treatment 1 active_not_recruiting NCT05884333
Cord Blood Transplant in Adults With Blood Cancers No drug interventions treatment 2 recruiting NCT03664635
MB-CART20.1 Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT05583318
Living Conditions After Non-Hodgkin's Lymphoma in France No drug interventions Not Available Not Available recruiting NCT00596154
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma No drug interventions treatment 2 completed NCT04757259
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib Not Available Not Available no_longer_available NCT05134740
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). No drug interventions treatment 1 recruiting NCT04586478
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 recruiting NCT02961881
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma treatment 1 completed NCT03789097
Vaccination With Flt3L, Radiation, and Poly-ICLC treatment 1 / 2 recruiting NCT01269593
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study diagnostic 0 active_not_recruiting NCT01746849
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation treatment 2 active_not_recruiting NCT01458366
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide treatment 1 / 2 completed NCT02639559
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies treatment 2 completed NCT03765177
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies No drug interventions treatment 1 / 2 recruiting NCT00285259
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) No drug interventions treatment 2 completed NCT00610883
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma treatment 2 completed NCT00571493
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma treatment 1 / 2 completed NCT00550615
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT01755975
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma treatment 1 / 2 completed NCT02050347
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) No drug interventions treatment 1 active_not_recruiting NCT02611323
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) treatment 1 / 2 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT03188965
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas treatment 1 completed NCT00574730
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma treatment Not Available completed NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor treatment 2 completed NCT05806099
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL No drug interventions treatment 1 / 2 recruiting NCT00443976
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma treatment 1 completed NCT02848274
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome No drug interventions Not Available Not Available recruiting NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT04156828
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma treatment 1 terminated NCT03236857
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies treatment 1 completed NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors treatment 2 completed NCT02659943
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies treatment 1 completed NCT01182415
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma No drug interventions treatment 2 completed NCT01316146
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) No drug interventions treatment 1 withdrawn NCT02919670
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma No drug interventions treatment Not Available completed NCT02391480
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer treatment 1 completed NCT02057445
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma No drug interventions treatment 1 completed NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT01598025
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor treatment Not Available terminated NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match treatment 2 terminated NCT01326728
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions Not Available Not Available terminated NCT01290549
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma treatment 1 completed NCT01281917
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT01042717
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection treatment Not Available unknown_status NCT00973804
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders treatment 1 terminated NCT00856245
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma treatment 2 completed NCT00837200
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies treatment 2 terminated NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT00807196
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma treatment 1 / 2 unknown_status NCT00739141
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. treatment 2 completed NCT00718757
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies treatment 1 completed NCT00432562
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. treatment 1 completed NCT00301301
A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Not Available Not Available completed NCT00301288
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL). No drug interventions Not Available Not Available completed NCT00193440
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT00193505
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma treatment 2 completed NCT00193479
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma treatment 2 completed NCT00179673
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma treatment 2 completed NCT00091676
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma No drug interventions treatment 3 unknown_status NCT00054834
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma treatment 1 terminated NCT00003500
Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma treatment 2 terminated NCT05349266
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy No drug interventions treatment 1 recruiting NCT05206071
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment Not Available recruiting NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases No drug interventions treatment 0 recruiting NCT04447547
Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment Not Available recruiting NCT04160195
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma treatment 1 terminated NCT04155840
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 terminated NCT04028440
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 0 unknown_status NCT03974243
Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT03797261
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies treatment 1 terminated NCT03792815
Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT03456466
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma treatment 1 / 2 unknown_status NCT03317899
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma treatment 2 completed NCT03074825
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma treatment 1 terminated NCT03018223
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT prevention 1 completed NCT02872987
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial No drug interventions Not Available Not Available recruiting NCT02856685
A Study of Mitoxantrone Hydrochloride Liposome Infusion treatment 1 / 2 unknown_status NCT02782845
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) treatment 4 completed NCT02723071
A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) treatment 1 / 2 completed NCT02722733
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma treatment 3 unknown_status NCT02719821
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation No drug interventions supportive_care Not Available completed NCT02697552
Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma treatment 1 completed NCT02624986
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants treatment 1 / 2 terminated NCT02453087
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma treatment 1 completed NCT02408042
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) treatment 1 / 2 withdrawn NCT02360111
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant treatment Not Available terminated NCT02315118
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies treatment 1 / 2 unknown_status NCT02259556
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas No drug interventions treatment 1 / 2 recruiting NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT02199288
Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting No drug interventions Not Available Not Available completed NCT02059239
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma treatment 1 / 2 completed NCT02006485
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies treatment 1 completed NCT01998893
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma treatment 2 completed NCT01980654
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma treatment 2 completed NCT01969682
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 basic_science 1 withdrawn NCT01969695
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma treatment 1 completed NCT01929265
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT01878890
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. treatment 1 completed NCT01851551
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL treatment 1 / 2 completed NCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT01763398
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study No drug interventions Not Available Not Available completed NCT01745913
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies treatment 2 terminated NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL treatment 1 terminated NCT01704742
Prospective Study of Lymphoproliferative Diseases No drug interventions Not Available Not Available withdrawn NCT01699581
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant No drug interventions treatment 2 terminated NCT01684865
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma Not Available Not Available completed NCT01609816
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma treatment 1 terminated NCT01585688
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL No drug interventions treatment 1 / 2 terminated NCT01491841
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma treatment 1 completed NCT01461928
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab treatment 3 completed NCT01458288
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease treatment 2 completed NCT01408563
Reduced Intensity Double Umbilical Cord Blood Transplantation treatment 2 completed NCT01402687
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) No drug interventions Not Available Not Available completed NCT01388959
A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT01339572
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation supportive_care 2 completed NCT01300793
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide treatment 1 terminated NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT01300026
AMG 319 Lymphoid Malignancy FIH No drug interventions treatment 1 completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT01221857
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies treatment 1 / 2 completed NCT01200589
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy treatment 3 terminated NCT01187810
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL treatment 1 terminated NCT01180049
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma treatment 4 completed NCT01164475
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms treatment 4 completed NCT01164345
Mozobil for Autologous Stem Cell Mobilization treatment 2 completed NCT01153971
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas treatment 2 completed NCT01144754
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT Not Available Not Available terminated NCT01144364
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) treatment 3 completed NCT01133158
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial treatment 2 completed NCT01118845
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 2 completed NCT01103388
Rituximab Maintenance After Autologous Transplantation treatment 3 terminated NCT01032148
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma treatment 1 terminated NCT01021423
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). treatment 3 terminated NCT01007292
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment treatment 2 completed NCT00988013
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies No drug interventions treatment Not Available completed NCT00984165
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions treatment 2 terminated NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT00952237
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF treatment 1 completed NCT00944905
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) No drug interventions treatment 1 completed NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35 treatment 2 terminated NCT00931229
Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients prevention Not Available unknown_status NCT00903812
IMPACT Non Hodgkins Lymphoma (NHL) Study No drug interventions Not Available Not Available completed NCT00902434
Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era No drug interventions Not Available Not Available completed NCT00896454
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium treatment 2 completed NCT00877006
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study treatment 3 completed NCT00864942
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) treatment 1 completed NCT00842114
Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL) treatment 2 completed NCT00825149
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma treatment 1 completed NCT00818480
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 treatment 2 completed NCT00809341
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma treatment 2 terminated NCT00802113
Autologous and Allogeneic Transplant for Relapsed Lymphoma treatment 1 / 2 completed NCT00794638
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma treatment 1 completed NCT00791011
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat treatment 1 completed NCT00788606
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma treatment 2 terminated NCT00775957
Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available terminated NCT00741325
Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). Not Available Not Available completed NCT00719472
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) treatment 3 completed NCT00713882
Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors No drug interventions Not Available Not Available completed NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT treatment 2 completed NCT00697671
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies treatment 1 completed NCT00693602
Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma supportive_care 1 completed NCT00685997
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas No drug interventions Not Available Not Available completed NCT00670592
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies treatment 1 / 2 completed NCT00659425
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma treatment 1 completed NCT00648037
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT treatment Not Available completed NCT00646750
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom treatment 2 completed NCT00612183
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma treatment 2 completed NCT00608907
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) treatment 1 completed NCT00606216
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy No drug interventions Not Available Not Available completed NCT00597519
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy treatment 2 completed NCT00588328
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning No drug interventions diagnostic 1 completed NCT00588263
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer No drug interventions Not Available Not Available withdrawn NCT00582933
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor treatment 2 completed NCT00581815
Spectroscopy With Surface Coils and Decoupling No drug interventions diagnostic 1 completed NCT00581646
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance No drug interventions Not Available Not Available completed NCT00579917
Behavioral Intervention For BMT/SCT Survivors No drug interventions Not Available Not Available completed NCT00576758
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma treatment 2 completed NCT00577161
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL treatment 3 withdrawn NCT00575068
Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT00569842
Investigation of the Cylex® ImmuKnow® Assay No drug interventions Not Available Not Available completed NCT00556699
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma treatment 1 completed NCT00547534
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma treatment 2 completed NCT00533728
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma treatment 1 completed NCT00517049
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) treatment 2 completed NCT00516152
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT treatment 2 completed NCT00510471
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma No drug interventions Not Available 2 terminated NCT00510315
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant No drug interventions Not Available Not Available completed NCT00504751
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL treatment 2 completed NCT00491491
Zevalin-beam for Aggressive Lymphoma treatment 3 completed NCT00491127
Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma treatment 2 completed NCT00487513
Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials No drug interventions Not Available Not Available completed NCT00475332
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar treatment 2 terminated NCT00469729
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy treatment 2 / 3 completed NCT00463463
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma treatment 3 unknown_status NCT00452127
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma No drug interventions treatment 1 / 2 terminated NCT00430352
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. treatment 4 completed NCT00421213
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers treatment 2 completed NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies treatment 1 / 2 completed NCT00389051
A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma treatment 1 completed NCT00384553
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma treatment 1 / 2 unknown_status NCT00369707
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL treatment 2 completed NCT00368355
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts treatment 2 completed NCT00354926
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma treatment 1 completed NCT00352846
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss treatment 3 completed NCT00343564
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma treatment 1 / 2 completed NCT00341952
Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT00336583
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT00337259
Gemcitabine for Marginal Zone Lymphoma treatment 2 terminated NCT00323323
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas treatment 1 completed NCT00312845
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma treatment 3 completed NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT00298779
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma. treatment 1 completed NCT00285428
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT00283439
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma supportive_care 1 / 2 completed NCT00277160
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer prevention 4 completed NCT00276003
INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. treatment 2 completed NCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies No drug interventions treatment 2 terminated NCT00274651
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas treatment 2 terminated NCT00273936
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Not Available 1 completed NCT00269113
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma treatment 3 completed NCT00262210
A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers treatment 2 completed NCT00250861
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma treatment 2 terminated NCT00250718
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach treatment 2 terminated NCT00225212
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma treatment 2 completed NCT00220285
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma treatment 2 completed NCT00201877
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma treatment 2 completed NCT00201318
A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen treatment 2 completed NCT00183950
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy treatment 1 / 2 terminated NCT00183976
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas treatment 2 terminated NCT00184002
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas treatment 2 completed NCT00176930
Stem Cell Transplant for Hematological Malignancy treatment Not Available terminated NCT00163748
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma treatment 2 completed NCT00163761
Efficacy Study of Outpatient Therapy for Lymphoma treatment 2 completed NCT00151281
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma treatment 2 completed NCT00151320
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL treatment 1 / 2 completed NCT00147953
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma treatment 2 completed NCT00144677
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation prevention 2 completed NCT00144703
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation prevention 2 completed NCT00139841
Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab treatment 3 completed NCT00136474
Amifostine for Head and Neck Irradiation in Lymphoma treatment 2 completed NCT00133367
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus treatment 2 completed NCT00133302
Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809) No drug interventions treatment 3 terminated NCT00120198
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients treatment 2 terminated NCT00117897
Treatment for Subjects With Non-Hodgkin's Lymphoma treatment 2 completed NCT00115193
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma treatment 2 completed NCT00109356
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia No drug interventions treatment 1 / 2 unknown_status NCT00100477
Use of Topotecan in Patients With Refractory Acute Leukemia Not Available 2 completed NCT00100347
Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors treatment 1 terminated NCT00090727
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma No drug interventions treatment 1 unknown_status NCT00081783
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients No drug interventions treatment 2 unknown_status NCT00078598
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma treatment 3 unknown_status NCT00077961
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL treatment 1 / 2 terminated NCT00076349
SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT00069758
Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00062894
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab treatment 1 / 2 completed NCT00061425
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG treatment 1 / 2 completed NCT00057343
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma treatment 3 terminated NCT00057447
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients treatment 1 / 2 terminated NCT00054808
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00044902
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) treatment 2 completed NCT00043459
Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma. treatment 2 terminated NCT00041730
Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma No drug interventions treatment 2 unknown_status NCT00038545
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma treatment 2 completed NCT00022932
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP treatment 2 unknown_status NCT00022906
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement treatment 1 unknown_status NCT00022958
Expanded Access Study of Iodine-131 Anti-B1 Antibody treatment Not Available unknown_status NCT00022893
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma treatment Not Available unknown_status NCT00981760
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation treatment 2 / 3 recruiting NCT02581631
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas treatment 1 / 2 completed NCT00520130
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System treatment 1 / 2 completed NCT03904134
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) No drug interventions treatment Not Available active_not_recruiting NCT05144334
A Study of BTX-1188 in Subjects With Advanced Malignancies No drug interventions treatment 1 terminated NCT04035434
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) treatment 1 / 2 active_not_recruiting NCT00006434
Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma No drug interventions treatment 3 completed NCT00562224
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients treatment 1 completed NCT00113724
Study of TPI 287 in Patients With Advanced Malignancies treatment 1 completed NCT03297424
A Study of PLX2853 in Advanced Malignancies. No drug interventions treatment 1 completed NCT03958916
Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL No drug interventions Not Available Not Available recruiting NCT04459416
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma No drug interventions treatment 3 active_not_recruiting NCT00089596
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers No drug interventions treatment 1 / 2 completed NCT04540796
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 active_not_recruiting NCT01593696
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma No drug interventions treatment 1 completed NCT00538096
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma treatment 1 withdrawn NCT03682796
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma No drug interventions treatment 1 completed NCT00996996
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma treatment 2 completed NCT04024696
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients treatment 1 / 2 active_not_recruiting NCT06563596
Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma treatment 2 not_yet_recruiting NCT05794958
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel treatment 1 recruiting NCT01178658
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma treatment 2 unknown_status NCT02964858
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. No drug interventions treatment 3 unknown_status NCT01181258
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies treatment 2 completed NCT02978235
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma No drug interventions treatment 1 terminated NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer treatment 2 recruiting NCT01868035
Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP treatment 2 completed NCT01969435
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma treatment 2 completed NCT01998035
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies treatment 1 / 2 terminated NCT05968963
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation No drug interventions supportive_care Not Available recruiting NCT00871663
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) treatment 1 completed NCT04684563
huCART19-IL18 in NHL/CLL Patients No drug interventions treatment 1 recruiting NCT00152139
Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT02836639
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma treatment 2 unknown_status NCT00578539
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE treatment Not Available terminated NCT01866839
Preventing Stem Cell Transplant Complications With a Blood Separator Machine No drug interventions treatment 1 / 2 completed NCT00354822
Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. treatment 2 terminated NCT03185325
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT05296525
Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL No drug interventions treatment 1 / 2 terminated NCT06323525
TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma treatment 1 / 2 recruiting NCT04666025
SARS-CoV-2 Donor-Recipient Immunity Transfer No drug interventions Not Available Not Available completed NCT04074330
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT02142530
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL treatment 1 completed NCT00329030
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) treatment 3 completed NCT03498430
Copanlisib Chinese PK Study basic_science 1 completed NCT05114330
Secondary Central Nervous System Lymphoma Registry - Charité No drug interventions Not Available Not Available recruiting NCT00002348
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma treatment 2 completed NCT00114348
ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia No drug interventions treatment 4 completed NCT01403948
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) treatment 1 completed NCT00094848
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT01490957
Functional Assessment of Cancer Therapy - Bone Marrow Transplant No drug interventions Not Available Not Available unknown_status NCT03205657
Auto/Allo Tandem Transplant for Relapsed B-NHL No drug interventions Not Available Not Available completed NCT01097057
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells treatment 2 completed NCT05994157
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 not_yet_recruiting NCT05206357
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab treatment 1 recruiting NCT00302757
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT06190457
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT01754857
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL treatment 2 completed NCT05834426
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers No drug interventions Not Available Not Available not_yet_recruiting NCT02115126
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant No drug interventions treatment 2 withdrawn NCT06133426
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients No drug interventions prevention Not Available not_yet_recruiting NCT05618366
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 recruiting NCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion treatment 2 recruiting NCT00396266
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF treatment 2 completed NCT02595866
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer treatment 1 completed NCT05950165
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma treatment 1 / 2 recruiting NCT00429065
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Not Available Not Available unknown_status NCT02342665
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL treatment 1 / 2 completed NCT00097565
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies treatment 1 not_yet_recruiting NCT00240565
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma treatment 2 completed NCT00185965
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas treatment 1 / 2 completed NCT02710565
Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma No drug interventions basic_science Not Available completed NCT01996865
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. treatment 3 active_not_recruiting NCT05283720
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma treatment 2 recruiting NCT00923520
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies No drug interventions treatment 1 completed NCT00534820
Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease No drug interventions basic_science Not Available completed NCT01121120
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients supportive_care 2 terminated NCT01810120
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT No drug interventions treatment 1 / 2 completed NCT02055820
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL treatment 1 / 2 completed NCT01196520
Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) No drug interventions Not Available Not Available completed NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT03935282
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors No drug interventions supportive_care Not Available active_not_recruiting NCT01487031
Music Therapy on Nausea and Pain for Autologous Stem Cell No drug interventions supportive_care Not Available completed NCT03602131
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma treatment 2 unknown_status NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader No drug interventions treatment 1 / 2 recruiting NCT03131531
Bergamo Lymphoid Cancer Registry No drug interventions Not Available Not Available recruiting NCT04601831
'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL No drug interventions treatment 1 / 2 recruiting NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine treatment 1 active_not_recruiting NCT05176873
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants No drug interventions treatment 1 completed NCT03467373
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL treatment 1 active_not_recruiting NCT05938127
Impact of Respiratory Training in Lymphoma Survivors No drug interventions basic_science Not Available recruiting NCT02104427
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients treatment 2 completed NCT00168727
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma treatment 4 completed NCT05019976
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma No drug interventions treatment Not Available recruiting NCT01283776
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation prevention 2 completed NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression treatment 3 active_not_recruiting NCT00240591
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab No drug interventions Not Available Not Available completed NCT00322491
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients treatment 2 completed NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT00275262
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation treatment 2 terminated NCT04827862
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy treatment 2 recruiting NCT03713580
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT04000880
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health No drug interventions supportive_care Not Available active_not_recruiting NCT04775680
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma No drug interventions treatment 1 / 2 terminated NCT02417129
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma treatment 3 terminated NCT00188929
Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma No drug interventions diagnostic 2 completed NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies treatment 1 active_not_recruiting NCT00000689
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma treatment 1 completed NCT03000192
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life No drug interventions Not Available Not Available unknown_status NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers treatment 1 active_not_recruiting NCT04876092
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL treatment 1 active_not_recruiting NCT05106192
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. supportive_care Not Available not_yet_recruiting NCT02631044
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) treatment 1 completed NCT05181540
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation No drug interventions supportive_care 3 terminated NCT02367040
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) treatment 3 active_not_recruiting NCT05540340
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant No drug interventions treatment 1 recruiting NCT01421667
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT03344367
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 unknown_status NCT02072967
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT00324467
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment treatment 2 unknown_status NCT04892667
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG No drug interventions prevention Not Available recruiting NCT02682667
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols No drug interventions Not Available Not Available recruiting NCT04809467
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 active_not_recruiting NCT01307267
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab treatment 1 completed NCT03794167
BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma treatment 2 completed NCT05123001
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events No drug interventions supportive_care Not Available recruiting NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available recruiting NCT02389101
Molecular and Whole-body MR Imaging in Lymphomas No drug interventions diagnostic Not Available completed NCT00001301
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors No drug interventions Not Available Not Available completed NCT04957901
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Mature B Cell Non-Hodgkins Lymphoma (NHL). No drug interventions Not Available Not Available recruiting NCT03212404
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers treatment 1 recruiting NCT00342004
A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women No drug interventions Not Available Not Available completed NCT00061672
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma treatment 2 completed NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT03050268
Familial Investigations of Childhood Cancer Predisposition No drug interventions Not Available Not Available recruiting NCT00901069
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma treatment 1 completed NCT05529069
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients treatment 2 recruiting NCT03434769
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma treatment 1 active_not_recruiting NCT05037669
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma treatment 1 withdrawn NCT01333046
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL treatment 1 active_not_recruiting NCT00430846
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies treatment 1 completed NCT04356846
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 recruiting NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit No drug interventions treatment 2 terminated NCT05921812
Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients No drug interventions Not Available Not Available recruiting NCT05200312
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma treatment 2 recruiting NCT06116110
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU No drug interventions Not Available Not Available not_yet_recruiting NCT03573310
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS No drug interventions treatment 1 active_not_recruiting NCT03768310
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) No drug interventions treatment 1 withdrawn NCT03223610
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma treatment 1 / 2 recruiting NCT06045910
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT05839210
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors No drug interventions other Not Available recruiting NCT04718610
Heart Rate Variability, Vagus Nerve and Cancer No drug interventions supportive_care Not Available terminated NCT04618081
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) No drug interventions Not Available Not Available recruiting NCT01032681
EMD 521873 in Advanced Solid Tumors, MTD Finding No drug interventions treatment 1 completed NCT05381181
Safety and Efficacy Evaluation of Next-generation CD19-UCART No drug interventions treatment 1 not_yet_recruiting NCT01010295
A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae treatment 2 completed NCT00539695
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD treatment 2 completed NCT03645395
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) No drug interventions treatment 2 terminated NCT02566395
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies treatment 3 completed NCT00882895
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma treatment 2 active_not_recruiting NCT00950755
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology treatment 2 completed NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 completed NCT00426855
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) treatment 1 / 2 completed NCT00186355
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma No drug interventions treatment Not Available completed NCT03019055
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell No drug interventions treatment 1 completed NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies treatment 1 completed NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed NCT04478123
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer treatment 2 completed NCT00333008
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. treatment 2 unknown_status NCT01685008
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT06383338
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. basic_science 1 not_yet_recruiting NCT03000738
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas No drug interventions Not Available Not Available unknown_status NCT06470438
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 recruiting NCT04206943
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL No drug interventions treatment 1 / 2 unknown_status NCT02955043
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery No drug interventions supportive_care Not Available completed NCT02747043
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab treatment 3 completed NCT00553943
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis treatment 2 completed NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies treatment 1 completed NCT00268203
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Not Available 2 completed NCT02431403
ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma treatment 1 / 2 unknown_status NCT00082303
Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's Lymphoma No drug interventions treatment 1 / 2 completed NCT00529503
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL treatment 2 terminated NCT03483103
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) treatment 2 completed NCT03065790
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide No drug interventions Not Available Not Available terminated NCT00490490
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy treatment 2 terminated NCT03671590
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies treatment 1 terminated NCT00903890
Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT00989664
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma treatment 2 completed NCT01720264
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant treatment 2 completed NCT03528421
Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients treatment 1 unknown_status NCT03469921
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 No drug interventions Not Available Not Available completed NCT00002221
Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT01596621
A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment treatment 3 completed NCT00412321
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease treatment 1 completed NCT00332202
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin prevention 3 completed NCT03484702
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma treatment 2 completed NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation treatment 2 recruiting NCT05878184
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) treatment 1 recruiting NCT01956084
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma No drug interventions treatment 1 active_not_recruiting NCT00002284
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant treatment Not Available completed NCT00724984
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma treatment 1 / 2 completed NCT00779584
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) treatment 1 completed NCT00649584
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies treatment 1 terminated NCT02811679
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma treatment 2 completed NCT00509379
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma treatment 2 completed NCT04083079
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma No drug interventions treatment 4 unknown_status NCT03422679
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies treatment 1 / 2 terminated NCT03921879
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma No drug interventions treatment 1 unknown_status NCT01018979
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients No drug interventions treatment 2 completed NCT03806179
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL treatment 1 completed NCT01294579
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) treatment 2 completed NCT06018129
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT03448393
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies treatment 1 recruiting NCT05442515
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies treatment 1 / 2 recruiting NCT06573099
A Real-World Study on Extranodal Lymphoma No drug interventions Not Available Not Available not_yet_recruiting NCT01676805
Tissue Collection for Studies of Lymph Cancer No drug interventions Not Available Not Available recruiting NCT04637763
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) treatment 1 recruiting NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT05896774
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China treatment 1 active_not_recruiting NCT06120504
A Safety Study of SGN-35T in Adults With Advanced Cancers No drug interventions treatment 1 recruiting NCT06219356
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 not_yet_recruiting NCT03570892
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma treatment 3 active_not_recruiting NCT03930953
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) treatment 1 / 2 recruiting NCT04077723
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma treatment 1 / 2 recruiting NCT04217317
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma treatment 2 terminated NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT05065866
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy treatment 1 active_not_recruiting NCT05093335
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET No drug interventions diagnostic 0 recruiting NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT05219513
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma treatment 1 terminated NCT05255601
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma treatment 1 / 2 recruiting NCT05320809
Study of 3D189 in Patients With Hematologic Malignancies treatment 1 active_not_recruiting NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases treatment 2 recruiting NCT06149169
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma No drug interventions treatment 2 active_not_recruiting NCT06479356
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma treatment 2 recruiting NCT06541327
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection No drug interventions Not Available Not Available recruiting NCT00039676
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer No drug interventions Not Available Not Available active_not_recruiting NCT00339963
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma No drug interventions Not Available Not Available completed NCT00579163
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers No drug interventions Not Available Not Available active_not_recruiting NCT00840047
Methionine PET/CT Studies In Patients With Cancer diagnostic 2 recruiting NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) treatment 2 recruiting NCT03743246
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) treatment 1 / 2 terminated NCT03900598
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 active_not_recruiting NCT04210219
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 active_not_recruiting NCT04657224
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 1 active_not_recruiting NCT05207670
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies treatment 2 recruiting NCT05424822
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 recruiting NCT05721222
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) No drug interventions treatment 1 / 2 recruiting NCT06139406
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer No drug interventions treatment 1 recruiting NCT01843868
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP supportive_care Not Available withdrawn NCT05171647
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma treatment 3 recruiting NCT02500407
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) treatment 1 / 2 active_not_recruiting NCT02553447
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency No drug interventions treatment Not Available active_not_recruiting NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT04545333
The clonoSEQ® Watch Registry No drug interventions Not Available Not Available terminated NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma treatment 1 recruiting NCT05974410
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients Not Available Not Available available NCT05989204
TmCD19-IL18 in CD19+ Cancers No drug interventions treatment 1 recruiting NCT06002828
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors No drug interventions Not Available Not Available recruiting NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. treatment 1 recruiting NCT06088654
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT06508099
Vitamin A and D Supplementation in Allogeneic HCT treatment 2 recruiting NCT03598608
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) treatment 1 / 2 recruiting NCT04082936
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT04245839
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) treatment 2 active_not_recruiting NCT04434196
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 1 completed NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) treatment 2 active_not_recruiting NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers treatment 1 active_not_recruiting NCT05346809
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma treatment 2 recruiting NCT05389423
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas treatment 1 suspended NCT05824585
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT06522932
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy diagnostic 1 not_yet_recruiting NCT06447376
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab treatment 1 not_yet_recruiting NCT06510361
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a Complete Response With Upfront Chemoimmunotherapy treatment 2 not_yet_recruiting NCT01660451
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas treatment 2 completed NCT03220347
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas treatment 1 active_not_recruiting NCT04606433
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia No drug interventions treatment 1 recruiting NCT05595577
Improving Exercise Capacity With a Tailored Physical Activity Intervention No drug interventions supportive_care Not Available recruiting NCT05627856
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL No drug interventions treatment 1 / 2 recruiting NCT06004011
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) No drug interventions screening Not Available recruiting NCT01351545
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) No drug interventions Not Available Not Available recruiting NCT01796171
A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT03229200
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. treatment 4 enrolling_by_invitation NCT03610724
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients treatment 2 completed NCT03755414
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation treatment 1 completed NCT04896580
IIT2020-20-SHIRAZIP-WALK: Nature Walks No drug interventions supportive_care Not Available active_not_recruiting NCT05131815
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors No drug interventions supportive_care Not Available active_not_recruiting NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT05998642
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma treatment 2 recruiting NCT06462248
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies No drug interventions treatment 2 recruiting NCT05515406
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL No drug interventions treatment 1 recruiting NCT05574114
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma No drug interventions treatment 1 recruiting NCT06484985
Study of AXT-1003 in Subjects With Advanced Malignant Tumors. No drug interventions treatment 1 not_yet_recruiting NCT06299462
PTCy and ATG for MSD and MUD Transplants prevention 1 / 2 recruiting NCT06458439
Epcoritamab-CAR T Cells for Large B-cell Lymphomas treatment 2 not_yet_recruiting NCT04083170
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers treatment 2 terminated NCT05400109
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas treatment 1 active_not_recruiting NCT02953509
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma treatment 1 / 2 terminated NCT03192397
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT05665725
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma No drug interventions treatment 1 recruiting NCT06424379
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. No drug interventions Not Available Not Available active_not_recruiting NCT06427213
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma treatment 2 not_yet_recruiting NCT04231747
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL No drug interventions treatment 1 recruiting NCT06418204
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics No drug interventions Not Available Not Available not_yet_recruiting NCT05098613
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients No drug interventions treatment 1 recruiting NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT05583071
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL treatment 2 not_yet_recruiting NCT02624388
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) supportive_care 2 terminated NCT05800210
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases No drug interventions treatment 2 recruiting NCT04240808
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) No drug interventions treatment 1 active_not_recruiting NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study No drug interventions Not Available Not Available recruiting NCT05332054
Long-Term Follow-up Study No drug interventions Not Available Not Available enrolling_by_invitation NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma treatment 1 recruiting NCT06393335
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research No drug interventions treatment 0 recruiting NCT02180711
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma treatment 1 / 2 active_not_recruiting NCT02663297
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas No drug interventions treatment 1 active_not_recruiting NCT02690545
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL No drug interventions treatment 1 / 2 recruiting NCT04150913
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity treatment 2 active_not_recruiting NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT02875223
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas treatment 1 terminated NCT02732275
DS-3201b in Participants With Lymphomas No drug interventions treatment 1 active_not_recruiting NCT04167683
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT04735471
A Phase 1 Study of ADI-001 in B Cell Malignancies treatment 1 recruiting NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 recruiting NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy Not Available Not Available recruiting NCT01853631
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) No drug interventions treatment 1 recruiting NCT03310619
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies treatment 1 / 2 completed NCT03842696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation prevention 1 / 2 recruiting NCT03013218
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) treatment 1 active_not_recruiting NCT03056339
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies treatment 1 / 2 completed NCT05169658
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma treatment 2 recruiting NCT02298816
B-Cell Hematologic Malignancy Vaccination Registry No drug interventions Not Available Not Available withdrawn NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant supportive_care 2 active_not_recruiting NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT04068597
Study to Evaluate CCS1477 in Haematological Malignancies treatment 1 / 2 recruiting NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT05678998
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT03615105
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors treatment 2 terminated NCT04136275
CAR-37 T Cells In Hematologic Malignancies No drug interventions treatment 1 completed NCT05044039
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy treatment 1 recruiting NCT00626496
Family Study of Lymphoproliferative Disorders No drug interventions Not Available Not Available recruiting NCT00709033
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL No drug interventions treatment 1 active_not_recruiting NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell No drug interventions treatment 1 / 2 completed NCT02917083
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) No drug interventions treatment 1 recruiting NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation treatment 2 active_not_recruiting NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention treatment 1 active_not_recruiting NCT04500587
Phase 1 First in Human Study of ZN-d5 as a Single Agent No drug interventions treatment 1 recruiting NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies treatment 1 recruiting NCT06005649
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 / 2 not_yet_recruiting NCT06277011
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research No drug interventions treatment 0 recruiting NCT03265574
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? prevention 3 completed NCT05611853
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies treatment 1 / 2 terminated NCT06170216
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL) No drug interventions Not Available Not Available active_not_recruiting NCT03620578
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL treatment 2 active_not_recruiting NCT03779113
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma No drug interventions treatment 1 active_not_recruiting NCT04072393
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers No drug interventions supportive_care Not Available recruiting NCT04460235
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma treatment 4 recruiting NCT04673617
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant supportive_care 1 active_not_recruiting NCT03768505
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) treatment 2 terminated NCT04718675
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05299164
GVM±R in Patients With Relapsed or Refractory Aggressive NHL treatment 1 active_not_recruiting NCT05443165
The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients No drug interventions supportive_care Not Available not_yet_recruiting NCT05607199
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics treatment 1 recruiting NCT05605119
First in Human, Dose Escalation, Dose Expansion Study of AUR105 No drug interventions treatment 1 recruiting NCT03311126
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma treatment 2 terminated NCT05150405
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors No drug interventions treatment 1 recruiting NCT02287311
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) treatment 1 recruiting NCT05416554
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford No drug interventions supportive_care Not Available not_yet_recruiting NCT05784415
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell No drug interventions Not Available Not Available active_not_recruiting NCT06203652
The Pathogenesis and Prognostic Factors of Lymphoma No drug interventions Not Available Not Available recruiting NCT05688475
A Rollover Study of CC-122 treatment 1 active_not_recruiting NCT05664217
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma No drug interventions treatment 2 / 3 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT03188354
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma No drug interventions diagnostic Not Available completed NCT03913949
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies treatment 1 active_not_recruiting NCT04090268
Precision Exercise in Children With Malignant Hemopathies No drug interventions treatment Not Available recruiting NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT05205512
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial No drug interventions supportive_care Not Available active_not_recruiting NCT05420493
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT06180174
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma No drug interventions treatment 1 recruiting NCT03454451
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers treatment 1 completed NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation supportive_care 2 active_not_recruiting NCT04975555
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy treatment 2 recruiting NCT06176690
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas No drug interventions treatment 1 not_yet_recruiting NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation treatment 2 completed NCT04745832
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) treatment 3 terminated NCT05425992
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families No drug interventions Not Available Not Available recruiting NCT03744676
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) treatment 2 completed NCT00368082
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) No drug interventions treatment 1 active_not_recruiting NCT02626455
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) treatment 3 terminated NCT03117036
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III No drug interventions Not Available Not Available recruiting NCT03255018
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas treatment 2 completed NCT00398177
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease No drug interventions Not Available Not Available recruiting NCT02543879
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT03366272
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients treatment 2 / 3 active_not_recruiting NCT03706625
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment No drug interventions Not Available Not Available completed NCT04089215
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT05233033
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL No drug interventions treatment 1 suspended NCT02369016
Phase III Copanlisib in Rituximab-refractory iNHL treatment 3 completed NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors treatment 1 recruiting NCT03575351
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas No drug interventions treatment 3 completed NCT03666000
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL treatment 1 / 2 recruiting NCT04758650
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis No drug interventions diagnostic 2 recruiting NCT04982471
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study No drug interventions Not Available Not Available recruiting NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases treatment Not Available recruiting NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients treatment 2 recruiting NCT04684979
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 2 withdrawn NCT05053100
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study No drug interventions Not Available Not Available recruiting NCT05221385
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma treatment 1 terminated NCT01000753
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT02065869
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant treatment 1 / 2 terminated NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL treatment 2 recruiting NCT02417285
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. treatment 1 completed NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery No drug interventions Not Available Not Available completed NCT03571308
A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) treatment 1 / 2 completed NCT03733249
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study treatment 1 / 2 terminated NCT04860466
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma No drug interventions treatment 1 active_not_recruiting NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT04996706
Lymphoma Epidemiology of Outcomes Cohort Years 6-10 No drug interventions Not Available Not Available enrolling_by_invitation NCT05253495
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma treatment 2 recruiting NCT06101381
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma treatment 1 / 2 not_yet_recruiting NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention supportive_care 3 completed NCT06037018
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies No drug interventions treatment 1 recruiting NCT02509039
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) treatment 1 completed NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies treatment 1 active_not_recruiting NCT04052126
An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies No drug interventions supportive_care Not Available completed NCT04671693
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. No drug interventions prevention Not Available recruiting NCT04732845
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies treatment 1 recruiting NCT05205161
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 terminated NCT04419389
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) treatment 1 / 2 terminated NCT05005299
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation treatment 1 recruiting NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT04971304
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars Not Available Not Available completed NCT01494103
Administration of Donor T Cells With the Caspase-9 Suicide Gene treatment 1 active_not_recruiting NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation treatment 2 active_not_recruiting NCT03272633
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies No drug interventions treatment 0 terminated NCT02736357
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study No drug interventions Not Available Not Available withdrawn NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT04136756
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma treatment 1 completed NCT04502706
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 terminated NCT01141959
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients No drug interventions Not Available Not Available completed NCT05127811
A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma No drug interventions treatment 1 terminated NCT05556720
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial treatment 3 recruiting NCT00896493
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma treatment 2 completed NCT05844956
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 recruiting NCT02376699
Safety Study of SEA-CD40 in Cancer Patients treatment 1 terminated NCT04161118
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma treatment 2 terminated NCT05840575
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively No drug interventions Not Available Not Available recruiting NCT03802955
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT05169151
Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study No drug interventions Not Available Not Available withdrawn NCT03969693
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation No drug interventions Not Available Not Available not_yet_recruiting NCT05431179
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma treatment 3 withdrawn NCT04045028
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma treatment 1 terminated NCT03688451
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma treatment 2 active_not_recruiting NCT01992653
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma treatment 1 / 2 completed NCT04323657
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT03923504
Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx No drug interventions other Not Available completed NCT01938001
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) treatment 3 completed NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT00576654
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT02257242
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma treatment 1 completed NCT03238651
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) No drug interventions other 1 terminated NCT03316209
Identification of Occupational Exposures in Acute Hematologic Malignancy No drug interventions Not Available Not Available completed NCT03357627
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma other 1 completed NCT03772288
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) treatment 1 withdrawn NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL treatment 1 / 2 completed NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT05557903
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL No drug interventions treatment 1 recruiting NCT05528055
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors treatment 1 recruiting NCT05415098
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 recruiting NCT05410041
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05269940
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 / 2 recruiting NCT05188755
Fitness Assessment in Young Adults Recovered From Lymphoma No drug interventions diagnostic Not Available completed NCT05066958
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT No drug interventions prevention 1 / 2 recruiting NCT05025358
A Study of LP-118 in Patients With Advanced Tumors No drug interventions treatment 1 recruiting NCT05021770
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma treatment 1 / 2 not_yet_recruiting NCT04911478
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells No drug interventions Not Available Not Available enrolling_by_invitation NCT04689204
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies No drug interventions treatment 0 recruiting NCT04638270
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL No drug interventions treatment 0 not_yet_recruiting NCT04543305
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT04514393
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma treatment 2 recruiting NCT04504708
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies No drug interventions treatment 1 / 2 terminated NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL treatment 1 / 2 recruiting NCT04434833
A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available recruiting NCT04342117
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL Not Available Not Available terminated NCT04337606
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor treatment 1 / 2 recruiting NCT04293900
Diet, Physical Activity and Body Composition Changes During R-CHOP No drug interventions Not Available Not Available withdrawn NCT04237428
CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma No drug interventions treatment Not Available unknown_status NCT04227015
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy No drug interventions treatment 0 recruiting NCT04169932
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma No drug interventions treatment 0 unknown_status NCT04154228
Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI No drug interventions diagnostic Not Available unknown_status NCT04089527
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 completed NCT03971305
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL No drug interventions Not Available Not Available recruiting NCT03971318
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL No drug interventions Not Available Not Available recruiting NCT03925935
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation No drug interventions treatment 1 completed NCT03886649
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. treatment 1 terminated NCT03885947
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies treatment 1 completed NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT03790891
Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy No drug interventions treatment 0 unknown_status NCT03765593
Biomarkers in Primary Sjögren's Syndrome No drug interventions Not Available Not Available unknown_status NCT03711578
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) treatment 2 completed NCT03619993
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms No drug interventions other Not Available completed NCT03595813
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy No drug interventions basic_science Not Available active_not_recruiting NCT03595800
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen No drug interventions treatment 3 active_not_recruiting NCT03480087
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma No drug interventions Not Available Not Available completed NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant supportive_care 2 withdrawn NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product No drug interventions Not Available Not Available terminated NCT03379051
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL treatment 1 / 2 terminated NCT03373019
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 unknown_status NCT03369964
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma treatment 1 withdrawn NCT03355859
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 unknown_status NCT03323541
Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure Not Available Not Available completed NCT03301168
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT03289182
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) Not Available Not Available completed NCT03260231
Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma No drug interventions treatment Not Available unknown_status NCT03244930
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation treatment 2 unknown_status NCT03207256
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials treatment 2 terminated NCT03169790
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL treatment 1 / 2 withdrawn NCT03132584
Cyclophosphamide and Alemtuzumab In Lymphoma treatment 1 terminated NCT03127020
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients treatment 2 completed NCT03088709
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide prevention 2 recruiting NCT03057418
Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim No drug interventions treatment 1 completed NCT03052777
Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors No drug interventions supportive_care Not Available completed NCT03019666
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL treatment 1 completed NCT02996617
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia No drug interventions treatment 4 unknown_status NCT02973113
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) treatment 1 completed NCT02954406
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma treatment 1 terminated NCT02867618
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma treatment 1 / 2 terminated NCT02788084
Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow No drug interventions Not Available Not Available unknown_status NCT02703272
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma treatment 3 terminated NCT02702141
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 terminated NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) treatment 1 completed NCT02657447
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) treatment 1 withdrawn NCT02640833
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor treatment 1 withdrawn NCT02613598
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma treatment 1 completed NCT02602067
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients No drug interventions treatment 1 terminated NCT02581878
Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT02568683
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) treatment 1 / 2 terminated NCT02529813
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies treatment 1 completed NCT02526823
Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma treatment 4 unknown_status NCT02519270
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects No drug interventions treatment 1 terminated NCT02507479
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies treatment 2 unknown_status NCT02499003
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma treatment 2 completed NCT02497898
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma No drug interventions treatment 2 not_yet_recruiting NCT02488369
Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents No drug interventions diagnostic Not Available completed NCT02434484
Symbenda Post-Marketing Surveillance (PMS) No drug interventions Not Available Not Available completed NCT02432235
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma treatment 1 completed NCT02410252
Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies No drug interventions other Not Available completed NCT02406092
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A treatment 3 completed NCT02371161
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy No drug interventions treatment 2 recruiting NCT02339805
Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS No drug interventions other Not Available completed NCT02280785
Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas treatment 2 completed NCT02229682
Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy No drug interventions treatment 2 unknown_status NCT02187133
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma treatment 1 completed NCT02155582
Copanlisib Pharmacodynamic Study other 1 completed NCT02141100
Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma treatment 1 / 2 withdrawn NCT02098109
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma treatment 2 completed NCT02080416
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors treatment 0 terminated NCT02038933
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) treatment 2 completed NCT01987505
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma treatment 3 completed NCT01953692
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) treatment 1 completed NCT01947140
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies treatment 1 / 2 completed NCT01939327
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma treatment 2 completed NCT01914744
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL prevention 2 unknown_status NCT01908387
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms treatment 1 terminated NCT01900509
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT01871675
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies treatment 1 completed NCT01777152
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas treatment 3 completed NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT01745354
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) No drug interventions treatment 1 terminated NCT01663714
Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma. treatment 2 completed NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT01611298
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR prevention Not Available completed NCT01597778
Double Cord Versus Haploidentical (BMT CTN 1101) No drug interventions treatment 3 completed NCT01584141
Study of Lymphoma in Asia No drug interventions Not Available Not Available completed NCT01573000
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT01562509
PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care No drug interventions health_services_research Not Available unknown_status NCT01555853
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma treatment 1 terminated NCT01541072
Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation treatment Not Available terminated NCT01536561
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma treatment 1 completed NCT01534715
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia treatment 1 completed NCT01527045
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies prevention 2 completed NCT01516619
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia prevention 2 completed NCT01482754
Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma treatment Not Available completed NCT01479582
Providing Access to Cord Blood Units for Transplants No drug interventions treatment 2 withdrawn NCT01447056
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases No drug interventions treatment 1 completed NCT01410630
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma Not Available Not Available completed NCT01344876
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies No drug interventions treatment 1 completed NCT01343368
Preservation of Ovarian Function After Hematopoietic Cell Transplant supportive_care 2 terminated NCT01328626
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma treatment 1 completed NCT01263418
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas treatment 2 withdrawn NCT01232556
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy treatment 3 terminated NCT01224821
Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies treatment 2 completed NCT01196208
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 Not Available Not Available no_longer_available NCT01186458
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma treatment 2 terminated NCT01178645
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma treatment 2 unknown_status NCT01164696
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin Not Available Not Available completed NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors treatment 2 completed NCT01155817
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease treatment 1 completed NCT01148173
High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas treatment 2 unknown_status NCT01135849
B-Receptor Signaling in Cardiomyopathy No drug interventions Not Available Not Available completed NCT01124526
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma treatment 4 completed NCT01114256
FNA Tumor Sampling for CD137 Modulation: A Pilot Study No drug interventions Not Available Not Available terminated NCT01090414
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study treatment 1 / 2 terminated NCT01079013
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies treatment 2 unknown_status NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT01030536
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) treatment 1 / 2 completed NCT01026233
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) treatment 1 completed NCT01026415
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) treatment 1 completed NCT01019863
Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma. treatment 2 unknown_status NCT01015911
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma treatment 1 completed NCT00996593
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab treatment 2 completed NCT00992446
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma treatment 2 completed NCT00992758
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement treatment 1 completed NCT00982449
124I-FIAU Imaging in EBV and KSHV Associated Cancers No drug interventions basic_science Not Available completed NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy treatment 1 terminated NCT00947856
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study treatment 2 completed NCT00946023
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab treatment 2 terminated NCT00938041
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody treatment 2 completed NCT00933335
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab treatment 2 completed NCT00928018
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma treatment 3 completed NCT00916045
Pilot Study of Unrelated Cord Blood Transplantation treatment 2 terminated NCT00912223
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) No drug interventions treatment 2 completed NCT00907348
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma No drug interventions treatment 2 unknown_status NCT00871910
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) treatment 1 completed NCT00871702
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease No drug interventions treatment 1 completed NCT00866047
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma treatment 2 completed NCT00862719
Sitagliptin Umbilical Cord Blood Transplant Study treatment 2 completed NCT00859768
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients No drug interventions supportive_care Not Available completed NCT00837174
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study treatment 2 withdrawn NCT00808171
Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture supportive_care 4 completed NCT00733824
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma treatment 1 / 2 completed NCT00655837
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL treatment 1 completed NCT00644124
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma treatment 1 completed NCT00644371
Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT00626444
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) treatment 2 terminated NCT00578461
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE treatment Not Available terminated NCT00572637
Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas treatment 1 completed NCT00556452
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen treatment 1 / 2 completed NCT00538551
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases No drug interventions Not Available Not Available unknown_status NCT00536835
Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma No drug interventions treatment 1 completed NCT00534989
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT No drug interventions treatment Not Available completed NCT00503451
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors treatment 1 completed NCT00500058
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 treatment 1 completed NCT00481832
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma treatment 2 terminated NCT00482053
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT treatment 2 terminated NCT00455897
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma treatment 2 terminated NCT00444912
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) treatment 2 completed NCT00435916
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma treatment 2 completed NCT00432419
Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy. No drug interventions treatment 1 / 2 terminated NCT00413959
VELCADE,Rituximab,Cyclophosphamide and Decadron treatment 2 terminated NCT00398411
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells prevention 3 completed NCT00383097
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT00374699
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas treatment 1 / 2 completed NCT00367497
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma treatment 2 terminated NCT00350181
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT treatment 2 completed NCT00347971
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma treatment 1 completed NCT00341705
The Second Multicenter Hemophilia Cohort Study No drug interventions Not Available Not Available completed NCT00328237
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation No drug interventions treatment 2 unknown_status NCT00322387
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients treatment 2 completed NCT00322842
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients treatment 2 completed NCT00319332
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen treatment 3 withdrawn NCT00306111
Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma treatment 2 completed NCT00283985
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma treatment 2 completed NCT00268983
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma treatment 3 completed NCT00261677
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy treatment 3 completed NCT00240578
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab No drug interventions Not Available Not Available completed NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies treatment 1 / 2 completed NCT00232440
Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma No drug interventions treatment 1 / 2 completed NCT00196885
Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training treatment 2 completed NCT00188370
Ultrasound Biomicroscopy - Apoptosis No drug interventions diagnostic 2 completed NCT00187161
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL treatment 2 completed NCT00187070
Large Cell Lymphoma Pilot Study III treatment Not Available completed NCT00185393
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy treatment 3 completed NCT00185445
Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL treatment 2 completed NCT00186589
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL treatment 1 completed NCT00185731
Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma treatment 2 completed NCT00177554
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma No drug interventions treatment 2 completed NCT00156013
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) treatment 1 / 2 completed NCT00154440
Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation treatment 3 unknown_status NCT00147485
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer treatment 1 terminated NCT00145652
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. treatment 3 completed NCT00145613
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies No drug interventions treatment 2 completed NCT00143559
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies No drug interventions treatment 2 completed NCT00141297
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer treatment 1 completed NCT00117156
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma treatment 2 completed NCT00103610
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients treatment 3 completed NCT00103779
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma treatment 1 completed NCT00100737
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) treatment 2 terminated NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT00088530
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) treatment 3 completed NCT00067288
Meaning-Centered Psychotherapy in Advanced Cancer No drug interventions educational_counseling_training 2 completed NCT00067002
Randomized Double Cord Blood Transplant Study treatment 2 completed NCT00062868
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma No drug interventions treatment 1 completed NCT00045877
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments treatment 2 / 3 completed NCT00045864
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. treatment 2 completed NCT00044551
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00039910
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia No drug interventions prevention 3 completed NCT00025662
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS No drug interventions treatment 2 completed NCT00026910
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT00019708
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma treatment 1 terminated NCT00003498
Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma treatment 2 terminated NCT00002003
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas treatment 2 completed NCT00001571
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines No drug interventions Not Available Not Available completed NCT00001575
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia No drug interventions treatment 1 / 2 completed NCT00001120
A Study of Patients With AIDS Syndrome No drug interventions Not Available Not Available completed NCT00000801
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma treatment 2 completed NCT00000723
The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer treatment Not Available terminated NCT00000658
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma treatment 3 completed NCT00000703
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members treatment Not Available completed NCT04590820
Oral Tazemetostat in Combination With Rituximab in R/R FL treatment 2 terminated NCT00566696
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies treatment 2 completed NCT01829958
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy treatment Not Available active_not_recruiting NCT04702425
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) treatment 1 terminated NCT02875548
A Study to Assess the Long-term Safety of Tazemetostat treatment 1 / 2 enrolling_by_invitation NCT02265731
Study Evaluating Venetoclax in Subjects With Hematological Malignancies treatment 1 / 2 completed NCT03260101
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study No drug interventions Not Available Not Available unknown_status NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies treatment 1 not_yet_recruiting NCT00186823
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT05225584
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors treatment 1 recruiting NCT04537715
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels treatment 1 completed NCT03849651
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies treatment 2 active_not_recruiting NCT02790515
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation treatment 2 recruiting NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT03229876
Safety and Efficacy Evaluation of CD19-UCART No drug interventions treatment Not Available suspended NCT01663766
Phase I Study of Milatuzumab for Graft Versus Host Disease treatment 1 terminated NCT03199066
Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL) No drug interventions Not Available Not Available recruiting NCT02259348
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation treatment 2 terminated NCT01929941
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies treatment 1 terminated NCT01707628
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab prevention Not Available completed NCT01396070
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level treatment 2 completed NCT01220297
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT treatment 2 terminated NCT01050764
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells treatment 1 / 2 terminated NCT00710528
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT02646098
CD34+ Selected ASCT for Aggressive Lymphomas No drug interventions treatment 2 active_not_recruiting NCT00726934
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients No drug interventions supportive_care Not Available completed NCT00323934
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma treatment 1 completed NCT01063439
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL) treatment 2 unknown_status NCT05554939
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL treatment 1 / 2 recruiting NCT06285422
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) treatment 1 recruiting NCT00901225
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant treatment 2 completed NCT00001830
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants No drug interventions treatment 1 completed NCT00838357
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). treatment 3 completed NCT02099266
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment No drug interventions treatment Not Available completed NCT00193466
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 completed NCT00058773
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease No drug interventions treatment 1 terminated NCT00364676
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease No drug interventions treatment 1 completed NCT00179660
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) treatment 2 completed NCT00126191
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma treatment 2 terminated NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant treatment 2 completed NCT01610180
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) treatment 2 completed NCT00764829
Blood Samples to Evaluate Biomarkers of Donor Chimerism No drug interventions Not Available Not Available completed NCT01342289
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide treatment 1 completed NCT00051701
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma treatment 1 / 2 terminated NCT00003501
Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma treatment 2 terminated NCT04240704
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL No drug interventions treatment 1 active_not_recruiting NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies treatment 1 terminated NCT01517581
Brown Fat Activity and White Fat Accumulation No drug interventions Not Available Not Available completed NCT00597714
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant No drug interventions treatment 2 completed NCT00665314
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). treatment 2 completed NCT02518750
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma treatment 2 terminated NCT01733238
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00651443
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma treatment 1 terminated NCT00161590
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma treatment 1 completed NCT00001379
Treatment and Natural History Study of Lymphomatoid Granulomatosis treatment 2 active_not_recruiting NCT04756726
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma treatment 1 / 2 recruiting NCT05370547
Chidamide Bridging for CAR-T Therapy treatment 1 / 2 recruiting NCT06014073
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL treatment 1 / 2 recruiting NCT01316523
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma treatment 2 active_not_recruiting NCT00840853
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT treatment 1 active_not_recruiting NCT04796675
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies treatment 1 recruiting NCT04497688
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma No drug interventions prevention Not Available unknown_status NCT02750670
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT02473523
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia No drug interventions supportive_care Not Available terminated NCT02007811
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination No drug interventions treatment 1 / 2 unknown_status NCT01904175
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant No drug interventions Not Available Not Available completed NCT01789723
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn prevention 1 withdrawn NCT01527422
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL treatment 1 / 2 completed NCT01018758
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy prevention 2 completed NCT00926757
Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B prevention 4 completed NCT00909948
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT00887718
Positron Emission Tomography(PET) in Lymphoma Assessment No drug interventions diagnostic Not Available completed NCT00834951
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma No drug interventions treatment 2 completed NCT00714259
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies treatment 2 / 3 terminated NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD treatment Not Available terminated NCT00477945
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL treatment 1 completed NCT00460694
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies No drug interventions treatment 1 / 2 completed NCT00413036
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma treatment 2 completed NCT00395967
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone treatment 2 terminated NCT00384150
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) treatment 3 terminated NCT00363636
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) treatment 3 terminated NCT00143871
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma treatment 2 completed NCT00143884
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood No drug interventions educational_counseling_training 2 terminated NCT00141700
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma treatment 2 terminated NCT00038818
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation No drug interventions treatment Not Available terminated NCT00038779
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States No drug interventions treatment Not Available terminated NCT00013533
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies No drug interventions treatment 0 completed NCT00001430
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas No drug interventions treatment 2 completed